Thursday, June 08, 2023 1:06:41 PM
It wasn't Anavex's fault and it was far out of line for that CRO to be so slow
You are being mighty generous to Missling to automatically fault the CRO entirely (contractually unable to publicly give their side of the story) when most likely blame is to be shared among several entities. If you want to believe Missling's every word as gospel I would love to sell you a few things. Who hired the CRO? Who writes their checks? Who communicates with them about progress and problems? Do they have any responsibility?
What is the process to get to the final database lock?
Patients come in for their final visits and there will be vital signs, physical exam, scales (ADAS-Cog, ADCS-ADL, etc), labs, AE review, medication accounting/dispensing etc.... at each site, the research coordinator (under the supervision of the PI) compiles the data and enters it into the electronic data capture software (i.e Imedidata, Rave -- all P2 and P3 studies have been digital x years). The CRO reviews the data and sends DCF's back to the site to provide clarifying statements if needed. Then, periodically the CRO sends a clinical research associate (CRA) to the site to find problems and correct them. This is a repetitive exercise as the study proceeds. Every 6 - 12 months, for most larger studies and all P3's I've done, the CRO will do database locks to make sure all sites are staying up to date. The CRO and sponsor communicate back and forth. If there was a problem, Missling knew about it well before November 28.
What might happen if a site is having trouble. A few years back, we lost 2 coordinators back to back. The sponsor for one more larger study worked with the CRO to send a temporary coordinator to do a handful of patient visits and entry until we had hired another CRC at our site. Near the end of studies, we get a couple emails a week announcing the impending database lock and to talk to them if we are going to have any issues. Emails let us know how many DCF's are left (even letting us know how other sites are doing). The CRO and sponsor will both contact sites that are lagging and try to get them to finish before the date. I have never heard of a database lock being missed by more than one week. Did Missling pick up the phone to talk to the PI? Did Missling release some funds to allow the CRO to provide more help if it was needed or was he still pinching every penny? He blamed the CRO for Avatar, blames the CRO for AD 2b. It's nice to know where the buck stops.
If indeed the database lock was 4-5 months late, blame can be shared among the site (PI/staff), CRO and sponsor/Missling
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
